Pharma M&A is no longer just about chasing the next blockbuster; it’s about platforms, production, and strategic control across the value chain. The race to secure capacity is rapidly redefining what it means to buy growth. For industry executives, the urgent question in 2026 and beyond is, “What parts of the value chain must we own to stay ahead of the competition?” Overall, strategic pharma deal value through November 15, 2025, jumped up by 79% compared with the same period in 2024, as the average deal size rose by more than 80%, signaling a decisive return of confidence in M&A.
Read the full article: Bain: M&A in Pharmaceuticals – Bigger, Bolder, and Far More Strategic //
Source: https://www.bain.com/insights/pharmaceuticals-m-and-a-report-2026/